Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- The Evolution of the MDx Industry
- The Three Phases of the MDx Industry
- Phase One: Infectious Diseases
- Phase Two: Blood Screening
- Phase Three: Pharmacogenomic Testing, Genetic Testing, Predictive
Testing, and
- Companion Diagnostics
- Pharmacogenomic Testing
- Predictive Testing
- Genetic Testing
- Expert Commentary-MDx: Looking Ahead
- MDx Technologies and Platforms
- MDx Technologies
- PCR
- DNA Methylation
- RNA Interference
- MDx Platforms
- Microarrays and Nanoarrays
- Microfl uidics
- Multiplex Assays
- Changing Trends
- Pharmaceutical/MDx Alliances and Acquisitions
- Support from Regulatory Authorities
- Alliances Between Diagnostics and Technology-Based Companies
- Regulatory Environment and Advances in MDx
- Key Players in the MDx Field
- Roche Diagnostics
- Abbott Diagnostics
- Bayer Diagnostics/Siemens Medical Solutions Group
- Market Outlook
Tables:
- 1. Select Molecular Diagnostics for Infectious Agents
- 2. The Third Phase of the MDx Industry
- 3. Recent Alliances Between Research Organizations and
Pharmaceutical/Biotech Companies
- 4. AmpliChip CYP450 Test
- 5. Select PGx-Based Diagnostic Tests
- 6. Comparison of Molecular Tests
- 7. Select Pharma-Diagnostics Industry Alliances
- 8. Recent Alliances Between Diagnostic and Technology Companies
- 9. Key Mergers and Acquisitions in the MDx Market
- 10. Likely Impact of Increased Uptake of MDx Tests
- 11. Global Market Opportunities for Molecular Diagnostics, 2005-2010
- A. Current and Planned MDx Products at Celera Diagnostics
Figures:
- 1. The Three Phases of the Molecular Diagnostic Industry
- 2. Growth in Alliances Between Academia/Research Organizations and
Pharmaceutical/Biotech Companies, 2002-2006
- 3. Select Molecular Diagnostic Technologies and Platforms
- 4. Interrelationship Between Pharmaceutical/Biotech and Molecular
Diagnostics Companies
- 5. Future Diversifi cation of the MDx Market
|
Related Report
|
View Cart
